Ant Group Brings Alipay+ to the Philippines with Three New Mobile Wallets, AlipayHK, Kakao Pay and Touch ‘n Go eWallet
Ant Group, the operator of Alipay+, the global cross-border digital payments and marketing solution, today announced that a total of four mobile wallets are now accepted in the Philippines. These include AlipayHK (Hong Kong SAR), Kakao Pay (South Korea), Touch ‘n Go eWallet (Malaysia) and Alipay (Chinese mainland), which has been accepted by Filipino merchants since 2017. This enables travellers from these regions to enjoy a cashless experience, using just their home mobile wallets to make payment, improving the travel experience as digital payment options like mobile wallets become the norm for day-to-day transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904840228/en/
Mactan-Cebu International Airport, which saw 219% increase in passengers in the 1H of 2023, have integrated Alipay+ across 90% of its merchants (Photo: Business Wire)
The acceptance of three new mobile wallets, via Alipay+, comes as travellers return to the Philippines. According to the Department of Tourism (DOT), more than 3 million tourists have visited the Philippines from January 1 to July 19, 2023, reflecting continued robust recovery. The DOT also shared that inbound tourism receipts from January 1 to June 30, 2023, are more than 500% higher than the same period last year1. South Koreans top the list of international visitors to the Philippines, while Malaysia ranks in the top 102.
Alipay+ is currently accepted by merchants in Manila and Cebu, the top two most visited cities in the Philippines pre-pandemic in 20193. In the first half of 2023, Mactan-Cebu International Airport saw a 219% increase in passengers compared to the same period last year. In order to cater to the new expectations of digital-first travellers, the airport has integrated Alipay+ across 90% of its merchants, ensuring that tourists can enjoy a digitally-enhanced cashless experience from the moment they arrive in Cebu.
Athanasios Titonis, Aboitiz InfraCapital Chief Executive Officer assigned to MCIA, said: “At MCIA, we have always placed utmost importance on providing convenience and ease of travel through seamless processes and world-class services and amenities. The integration of Alipay+ gives our passengers that exceptional convenience and more payment options when they travel through MCIA.”
Mactan-Cebu International Airport (MCIA) is the second largest airport in the Philippines with over 11 million passengers annually, making it the second busiest airport in the country. With its strategic location and world-class facilities, MCIA aims to establish itself as the main tourism gateway of the country with exceptional travel experience, connecting the world to the Philippines. To date, MCIA is the first and only airport in the Philippines to receive the Airport Customer Experience (ACX) accreditation from the Airports Council International.
Commenting on this new development, Dr. Cherry Huang, General Manager of Alipay+ Offline Merchant Services at Ant Group, said: “Philippines and its many islands, such as Cebu, have long been a favourite destination for Asian travellers and we look forward to working with our local partners to enhance their travel experience. We believe that digital adoption and solutions will shape travellers’ expectations, particularly in the way the engage travel-related businesses, from airports and hospitality to F&B and retail stores. Our focus now is to work with more partners to onboard more merchants with Alipay+ across the Philippines, particularly local small businesses, and promote digital travel and travel recovery.”
Introduced by Ant Group in 2020, Alipay+ aims to enable local businesses, especially small and medium-sized businesses, to process a wide range of mobile payment methods and reach more than 1.4 billion regional and global consumers, through one-time integration and simple technical adaption. In addition to the Philippines, Alipay+ is also widely accepted in destinations including the Chinese mainland, Macao SAR, Singapore, Thailand, Japan and South Korea among others.
About Mactan-Cebu International Airport
Mactan-Cebu International Airport (MCIA) is the second largest airport in the Philippines. It serves over 11 million passengers annually, making it the second busiest airline hub in the country. MCIA is operated by a Filipino-led private consortium between Aboitiz InfraCapital (AIC), GMR Group of India, and Megawide Construction Corporation (MCC), under a concession agreement with the Philippine Government. With its strategic location and world-class facilities, MCIA aims to establish itself as the main tourism gateway of the country with exceptional travel experience, connecting the world to the Philippines. MCIA is accredited for the Airport Customer Experience (ACX) and the Airport Health Accreditation (AHA) by the Airports Council International.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
1 Manila Bulletin (19 July 2023): PH int’l tourists breach 3M mark, revenues hit P212B
2 Department of Tourism: Tourism demand statistics 2023
3 Department of Tourism: Visitor arrivals: January – December 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904840228/en/
Contact information
Scott Lai
scott.lai@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom